ReviewMolecular biology reports2026
Wogonin-mediated modulation of cellular signaling pathways: Mechanistic insights into neuroprotection.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative disorders and age-related cognitive decline remain significant global health challenges, with current therapies offering only symptomatic relief. Flavonoids have emerged as a promising alternative due to their multi-target actions and safety. One such is wogonin (5,7-dihydroxy-8-methoxyflavone), a root-specific flavone from Scutellaria species, which has shown strong neuroprotective potential. This review provides a comprehensive overview of biosynthesis, pharmacokinetics, and mechanistic insights into wogonin, which confer neuroprotection and cognitive resilience. Evidence from cellular and animal models highlights its ability to cross the blood-brain barrier and modulate key signaling pathways, including NF-κB, MAPK, PI3K/Akt, Nrf2/ARE, AMPK, and CREB/BDNF, thereby attenuating oxidative stress, neuroinflammation, mitochondrial dysfunction, and synaptic loss. Furthermore, we summarize preclinical and emerging clinical evidence supporting its role in aging-associated neurodegenerative disorders.
Indexed as
Identifiers
41706246What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.